JP2016538840A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016538840A5 JP2016538840A5 JP2016526026A JP2016526026A JP2016538840A5 JP 2016538840 A5 JP2016538840 A5 JP 2016538840A5 JP 2016526026 A JP2016526026 A JP 2016526026A JP 2016526026 A JP2016526026 A JP 2016526026A JP 2016538840 A5 JP2016538840 A5 JP 2016538840A5
- Authority
- JP
- Japan
- Prior art keywords
- rhaga
- protein
- column
- pccs2
- mccs1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020005541A JP7296327B2 (ja) | 2013-10-23 | 2020-01-17 | 組み換え糖タンパク質及びその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361894879P | 2013-10-23 | 2013-10-23 | |
| US61/894,879 | 2013-10-23 | ||
| US201361901942P | 2013-11-08 | 2013-11-08 | |
| US61/901,942 | 2013-11-08 | ||
| PCT/US2014/061789 WO2015061464A2 (en) | 2013-10-23 | 2014-10-22 | Recombinant glycoproteins and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020005541A Division JP7296327B2 (ja) | 2013-10-23 | 2020-01-17 | 組み換え糖タンパク質及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016538840A JP2016538840A (ja) | 2016-12-15 |
| JP2016538840A5 true JP2016538840A5 (enExample) | 2017-11-30 |
| JP6837334B2 JP6837334B2 (ja) | 2021-03-03 |
Family
ID=51871299
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016526026A Active JP6837334B2 (ja) | 2013-10-23 | 2014-10-22 | 組み換え糖タンパク質及びその使用 |
| JP2020005541A Active JP7296327B2 (ja) | 2013-10-23 | 2020-01-17 | 組み換え糖タンパク質及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020005541A Active JP7296327B2 (ja) | 2013-10-23 | 2020-01-17 | 組み換え糖タンパク質及びその使用 |
Country Status (33)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| EP3896164A1 (en) * | 2016-05-18 | 2021-10-20 | ModernaTX, Inc. | Polynucleotides encoding alpha-galactosidase a for the treatment of fabry disease |
| EP4667565A2 (en) | 2016-10-20 | 2025-12-24 | Sangamo Therapeutics, Inc. | Methods and compositions for the treatment of fabry disease |
| TW201829770A (zh) | 2017-01-10 | 2018-08-16 | 美商阿米庫斯醫療股份有限公司 | 用於治療fabry氏病之重組α-半乳糖苷酶A |
| WO2025092951A1 (en) * | 2023-11-03 | 2025-05-08 | Shanghai Vitalgen Biopharma Co., Ltd. | Recombinant adeno-associated viral vectors for treating fabry disease |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5356804A (en) * | 1990-10-24 | 1994-10-18 | Mount Sinai School Of Medicine Of The City Of New York | Cloning and expression of biologically active human α-galactosidase A |
| US5401650A (en) * | 1990-10-24 | 1995-03-28 | The Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of biologically active α-galactosidase A |
| US6458574B1 (en) | 1996-09-12 | 2002-10-01 | Transkaryotic Therapies, Inc. | Treatment of a α-galactosidase a deficiency |
| DK2374876T3 (en) | 1996-09-13 | 2016-05-30 | Shire Human Genetic Therapies | A process for the purification of alpha-galactosidase A |
| US6083725A (en) | 1996-09-13 | 2000-07-04 | Transkaryotic Therapies, Inc. | Tranfected human cells expressing human α-galactosidase A protein |
| AU734290B2 (en) | 1997-10-29 | 2001-06-07 | Genzyme Corporation | Compositions and methods for treating lysosomal storage disease |
| US20020081654A1 (en) * | 2000-04-07 | 2002-06-27 | Sandrin Mauro Sergio | Targeting hydrolase enzymes |
| US7138262B1 (en) * | 2000-08-18 | 2006-11-21 | Shire Human Genetic Therapies, Inc. | High mannose proteins and methods of making high mannose proteins |
| US7133354B2 (en) | 2002-08-26 | 2006-11-07 | Qualcomm Incorporated | Synchronization techniques for a wireless system |
| TWI328614B (en) * | 2002-12-23 | 2010-08-11 | Bristol Myers Squibb Co | Product quality enhancement in mammalian cell culture processes for protein production |
| CN100522988C (zh) * | 2003-04-09 | 2009-08-05 | 诺和诺德公司 | 糖peg化方法及由该方法生产的蛋白质/肽 |
| EP2134853B1 (en) * | 2007-04-03 | 2018-07-18 | Oxyrane UK Limited | Glycosylation of molecules |
| WO2009027041A1 (en) | 2007-08-31 | 2009-03-05 | F. Hoffmann-La Roche Ag | Glycosylation profile analysis |
| EP2421892A1 (en) * | 2009-04-20 | 2012-02-29 | Pfizer Inc. | Control of protein glycosylation and compositions and methods relating thereto |
| HUE030959T2 (en) * | 2010-03-02 | 2017-06-28 | Protalix Ltd | Stabilized alpha-galactosidase and its uses |
| US20120178105A1 (en) | 2011-01-10 | 2012-07-12 | Genzyme Corporation | Detection of globotriaosylceramide (glc) in human urine samples using an antibody sandwich |
| AU2011356137A1 (en) * | 2011-01-20 | 2013-08-15 | Protalix Ltd. | Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells |
| IN2014MN00740A (enExample) * | 2011-10-12 | 2015-05-22 | Synageva Biopharma Corp | |
| EP2620506A1 (en) | 2012-01-25 | 2013-07-31 | Arla Foods Amba | Method of producing a galacto-oligosaccharide-containing composition |
| TWI528785B (zh) | 2013-02-08 | 2016-04-01 | 瑞昱半導體股份有限公司 | 立體影像的調整裝置及其方法 |
| IL274646B (en) | 2013-03-08 | 2022-09-01 | Genzyme Corp | Integrated continuous production of medicinal substances from medical protein |
-
2014
- 2014-10-21 TW TW103136272A patent/TWI642782B/zh active
- 2014-10-21 TW TW111139854A patent/TW202332774A/zh unknown
- 2014-10-21 TW TW107130267A patent/TWI793159B/zh active
- 2014-10-22 MY MYPI2016700943A patent/MY178632A/en unknown
- 2014-10-22 SG SG10201803366PA patent/SG10201803366PA/en unknown
- 2014-10-22 CN CN202210146800.9A patent/CN114606217A/zh active Pending
- 2014-10-22 BR BR112016008086A patent/BR112016008086A2/pt not_active Application Discontinuation
- 2014-10-22 PE PE2016000543A patent/PE20160723A1/es unknown
- 2014-10-22 HR HRP20211197TT patent/HRP20211197T1/hr unknown
- 2014-10-22 PT PT147963466T patent/PT3060660T/pt unknown
- 2014-10-22 CA CA2927852A patent/CA2927852A1/en active Pending
- 2014-10-22 RS RS20210960A patent/RS62171B1/sr unknown
- 2014-10-22 PL PL14796346T patent/PL3060660T3/pl unknown
- 2014-10-22 MX MX2016005321A patent/MX392532B/es unknown
- 2014-10-22 KR KR1020167013333A patent/KR102298080B1/ko active Active
- 2014-10-22 KR KR1020217027690A patent/KR102479886B1/ko active Active
- 2014-10-22 CN CN202110161563.9A patent/CN112852784A/zh active Pending
- 2014-10-22 SI SI201431857T patent/SI3060660T1/sl unknown
- 2014-10-22 DK DK14796346.6T patent/DK3060660T3/da active
- 2014-10-22 SG SG11201602932WA patent/SG11201602932WA/en unknown
- 2014-10-22 CN CN201480070424.3A patent/CN105916984A/zh active Pending
- 2014-10-22 PH PH1/2016/500708A patent/PH12016500708B1/en unknown
- 2014-10-22 NZ NZ720384A patent/NZ720384A/en unknown
- 2014-10-22 LT LTEPPCT/US2014/061789T patent/LT3060660T/lt unknown
- 2014-10-22 JP JP2016526026A patent/JP6837334B2/ja active Active
- 2014-10-22 TN TN2016000140A patent/TN2016000140A1/en unknown
- 2014-10-22 EA EA201690826A patent/EA034515B1/ru not_active IP Right Cessation
- 2014-10-22 UA UAA201605455A patent/UA119857C2/uk unknown
- 2014-10-22 ES ES14796346T patent/ES2882562T3/es active Active
- 2014-10-22 EP EP20183936.2A patent/EP3778884A1/en active Pending
- 2014-10-22 EP EP14796346.6A patent/EP3060660B1/en active Active
- 2014-10-22 HU HUE14796346A patent/HUE055236T2/hu unknown
- 2014-10-22 WO PCT/US2014/061789 patent/WO2015061464A2/en not_active Ceased
- 2014-10-22 MY MYPI2019005029A patent/MY197247A/en unknown
- 2014-10-22 US US15/030,555 patent/US11208644B2/en active Active
- 2014-10-22 AU AU2014340152A patent/AU2014340152A1/en not_active Abandoned
- 2014-10-23 UY UY0001035794A patent/UY35794A/es not_active Application Discontinuation
-
2016
- 2016-04-11 DO DO2016000079A patent/DOP2016000079A/es unknown
- 2016-04-21 IL IL245255A patent/IL245255B/en active IP Right Grant
- 2016-04-21 CL CL2016000961A patent/CL2016000961A1/es unknown
- 2016-05-17 CR CR20160225A patent/CR20160225A/es unknown
-
2020
- 2020-01-17 JP JP2020005541A patent/JP7296327B2/ja active Active
- 2020-02-11 IL IL272609A patent/IL272609B/en unknown
- 2020-12-21 AU AU2020294173A patent/AU2020294173A1/en not_active Abandoned
-
2021
- 2021-09-22 US US17/482,193 patent/US20220064617A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016538840A5 (enExample) | ||
| JP2013231081A5 (enExample) | ||
| GB0102687D0 (en) | Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them | |
| JP2016056206A5 (enExample) | ||
| JP2012041356A5 (enExample) | ||
| MXPA02012164A (es) | Derivados de tiofeno activos como inhibidores de cinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden. | |
| Gutiérrez et al. | Cerebral protection, brain repair, plasticity and cell therapy in ischemic stroke | |
| IL159843A0 (en) | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | |
| JP2016530323A5 (enExample) | ||
| IL160744A0 (en) | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | |
| WO2006102596A3 (en) | Dosage regimen for the treatment of a traumatic brain injury with progesterone | |
| JP2011528895A5 (enExample) | ||
| JP2012236857A5 (enExample) | ||
| MY204380A (en) | Nonracemic mixtures and uses thereof | |
| CN102911250B (zh) | 酸性重组蛋白药物的纯化方法 | |
| WO2007078895A3 (en) | Modified release formulations of tramadol and uses thereof | |
| JP2017537927A5 (enExample) | ||
| ES2184561A1 (es) | Forma farmaceutica solida de administracion oral dispersable en agua para el tratamiento de la tuberculosis conteniendo refampicina, isoniazida, pirazinamida y piridoxina hidrocloruro, procedimiento para su obtencion y forma de presentacion de dicha forma farmaceutica. | |
| Sousa et al. | Hands-on laboratory class for biopharmaceutical pDNA quality control | |
| JP2018501247A5 (enExample) | ||
| Galeazzi et al. | SAT0196 Dekavil (F8-IL10), A Novel Therapeutic Approach for Rheumatoid Arthritis: Ongoing Phase IB Clinical Trial Results | |
| Huang et al. | Adalimumab plus methotrexate for the treatment of rheumatoid arthritis: a multi-center randomized, double-blind, placebo-controlled clinical study | |
| CA3231655A1 (en) | Novel polypeptide | |
| CN107281096A (zh) | 一种含帕拉米韦的水针剂及其制备方法 | |
| Anno et al. | POS0681 DRUG RETENTION RATE AND EFFECTIVENESS OF JAK INHIBITOR IN PATIENTS WITH DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS |